Product category:
Clinical chemistry analysis
News Release from: Cambridge BioScience | Subject: 3A4/BQ kit
Edited by the Laboratorytalk Editorial
Team on 02 December 2002
HTS kit for CYP3A4 inhibitors
High throughput screening kit provides all the necessary components and instructions for measuring the IC50 values of up to 38 test compounds in 96-well plates
Cambridge BioScience has introduced the new 3A4/Benzyloxyquinoline (BQ) high throughput inhibition screening kit for the rapid screening of potential inhibitors of CYP3A4 catalytic activity It has been estimated that CYP3A4 (an enzyme of the cytochrome P450 system) is significantly involved in the metabolism of more than half of commercially available drugs
This article was originally published on Laboratorytalk on 4 Jul 2005 at 8.00am (UK)
Related stories
Monoclonal antibody to mouse IPC
Inhibitory antibody reacts with a cell-surface molecule selectively expressed on mouse inteferon producing cells
Consequently, CYP3A4 is frequently associated with metabolism-based drug-drug interactions.
Obtaining a clear CYP3A4 inhibition profile may be crucial to successful lead development.
In addition to its importance in human drug metabolism, CYP3A4 is of interest because of its unusual kinetic properties.
The inhibitor screening kit, developed by Gentest, provides all the necessary components and instructions for measuring the IC50 values of up to 38 test compounds (in duplicate) in 96-well plates.
The 3A4/BQ kit can be used in-conjunction with the 3A4/BFC kit to help insure the identification of all potential CYP3A4 inhibitors.
Rapid testing for cytochrome P450 inhibitors is vitally important in the pharmaceutical industry.
Screening allows the identification of adverse interactions between new drugs and the human metabolism early on in the drug discovery process, eliminating these drugs before expensive clinical trials begin.
• Cambridge BioScience: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page

